Topical superpotent class I corticosteroids (CSs) are highly effective in the treatment of early-stage mycosis fungoides (MF) and are readily available, easily applied, and have minor side effects compared to other topical therapeutic options. Because MF is a chronic disease, prolonged treatment is needed, raising the concern of CS-induced cutaneous adverse effects (AEs). In this observational study, we aimed to evaluate the risk for skin AEs of clobetasol propionate cream 0.05% in patients with early-stage MF. Thirteen consecutive patients with MF were treated with clobetasol propionate cream 0.05% once or twice daily as monotherapy and were followed for 4 to 17 months. One participant was lost to follow-up, and the remaining 12 participants responded to treatment with topical clobetasol propionate with minimal side effects. With proper education and monitoring, topical CSs are a safe and effective mainstay of treatment for patches and flat plaques in patients with early-stage localized MF.
Download full-text PDF |
Source |
---|
J Dent Sci
January 2025
Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background/purpose: Discoid lupus erythematosus (DLE) serves as an interdisciplinary disease involved in dermatology and stomatology in many cases. The purpose of this study was to analyze the scientometric characteristics and research trends of DLE.
Materials And Methods: All the papers on DLE were comprehensively retrieved from the Scopus database.
F1000Res
January 2025
Dermatology, Venereology and Leprosy, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India.
Background: Hand eczema is a prevalent dermatological condition that significantly impacts the quality of life of affected individuals. Topical corticosteroids, such as Clobetasol Propionate, are commonly employed for management, but concerns regarding long-term use and potential side effects necessitate exploration of alternative treatments. This study protocol outlines a randomized controlled trial comparing the efficacy of topical Tofacitinib 2% ointment with Clobetasol Propionate 0.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Public Health Officer, Ethiopian Statistical Service, Bahirdar, Ethiopia.
Background: Corticosteroids are among the most frequently prescribed drugs in the world because they are extremely effective for the relief of symptoms of many inflammatory and immune disorders and other conditions. Corticosteroids have been a mainstay of pharmacotherapy in dermatological practice.
Objective: This study aimed to assess prescribing practices of corticosteroids in outpatient dermatology department of Injibara General Hospital, North-West Ethiopia, 2024.
Cureus
January 2025
Dermatology and Dermatologic Surgery, Prince Sultan Military Medical City, Riyadh, SAU.
Tumid lupus erythematosus (TLE) is a rare subtype of cutaneous lupus, which can present diagnostic challenges due to its overlapping features with other skin disorders. Understanding the clinical and histopathological characteristics of TLE is essential for accurate diagnosis and management. In this article, we describe a case of TLE in a 45-year-old man who presented with annular, urticarial, non-scarring plaques on the scalp associated with non-scarring alopecia in the affected area.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
The Dermatology Department of the Central Military Hospital of the Ministy of Defense, Baku, Azerbaijan.
The use of antidepressant medications in the treatment of lichen simplex chronicus (LSC) also known as neurodermatitis, is not well-documented in the literature. The primary aim of our study is to evaluate the impact of duloxetine 30 mg on the quality of life in patients with LSC, focusing on both pruritus and psychopathological aspects. The secondary aim is to investigate the relationship between LSC and anxiety and depression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!